Creek Parent, Inc. and Creek Feeder, L.P.
Creek Parent, Inc. is the acquisition holding entity used by Novo Holdings A/S to take Catalent, Inc. private. Catalent is a contract development and manufacturing organization (CDMO) providing drug- and biologic-development, delivery, and manufacturing services to pharmaceutical and biotech customers. The Creek Parent / Creek Feeder financing structure backs the Catalent take-private.
Company profile. Written by an AI model from public web sources; not checked for copying; not taken from the company's or the lender's SEC filing. — distinct from the SEC Schedule-of-Investments pricing data below. · AI-generated analysis. Not investment advice. May contain errors.
Lenders
Creek Parent, Inc. and Creek Feeder, L.P. is held by 6 BDC lenders in our parsed SEC filings: AGTC, ARCC, BXSL, GBDC, OBDC, OCSL.
Cross-lender loan pricing
Each row is one debt tranche at the BDC’s most recent filing that holds this borrower, widest spread first. Mark is the position’s fair value as a percent of par (100 = par). Spread is shown in basis points over the benchmark in the Rate column, normalized from each filing’s as-reported units — rows quoting different benchmarks are still not directly comparable. Compare like-for-like: a second-lien tranche, a different vintage, or an older filing should price wider even when the credit view is identical — check the Type and Filing columns before reading a gap as disagreement. Source: SEC EDGAR (public).
| BDC | Type | Rate | Cash spread (bps) | Mark (% of par) | Fair Value | Maturity | Filing |
|---|---|---|---|---|---|---|---|
| AGTC | 1L Sr Secured | SOFR | 500 | 100.0 | $122M | 2031-12 | 2026-08-07 |
| ARCC | 1L Sr Secured | SOFR | 500 | 100.0 | $206M | 2031-12 | 2026-07-29 |
| BXSL | 1L Sr Secured | SOFR | 500 | 98.5 | $67M | 2031-12-18 | 2026-08-06 |
| GBDC | 1L Sr Secured | SOFR | 500 | 98.5 | $55M | 2031-12 | 2026-08-03 |
| OBDC | 1L Sr Secured | SOFR | 500 | 99.2 | $112M | 2031-12 | 2026-08-05 |
| OCSL | 1L Sr Secured | SOFR | 500 | 98.5 | $37M | 2031-12-18 | 2026-08-05 |
Marks reflect each BDC’s own fair-value estimates as reported to the SEC, not traded prices. Private-credit loans are predominantly Level 3 under ASC 820 — valued from unobservable inputs and determined in good faith under the oversight of each BDC’s board (often by the adviser as valuation designee), so figures are estimates as of the period end each filing reports, not its filing date, and are not directly comparable across managers. Informational only; not investment advice or a valuation.
Ownership & deal activity
Verified headlines that signal an acquisition, merger, buyout, sponsor change, refinancing, or restructuring involving Creek Parent, Inc. and Creek Feeder, L.P.. A mention is not confirmation of a completed deal — verify against the linked source. Source: Google News.
- Codis Completes Acquisition of Catalent's Nottingham, UK Facility, Expanding Europe's Premier Spray Dry Network
- Codis Completes Acquisition of Catalent's Nottingham, UK Facility, Expanding Europe's Premier Spray Dry Network
- Codis Completes Acquisition of Catalent's Nottingham, UK Facility, Expanding Europe's Premier Spray Dry Network
- Codis Completes Acquisition of Catalent’s Nottingham, UK Facility
- List of 13 Acquisitions by Catalent (Aug 2026)
Headlines mentioning Creek Parent, Inc. and Creek Feeder, L.P.
Public headlines that name Creek Parent, Inc. and Creek Feeder, L.P., matched by company name and shown most-recent first. A mention is not an endorsement, a rating, or investment advice — verify anything material against the original source. Source: Google News.
- Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story?
- Scholar Rock removes Catalent facility from SMA drug application
- Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger
- Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
- Scholar Rock shifts apitegromab BLA to second fill-finish site after Catalent FDA inspection
- Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
- Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
- Codis Completes Acquisition of Catalent's Nottingham, UK Facility, Expanding Europe's Premier Spray Dry Network
Reading this table
When two business development companies lend to the same borrower, comparing how each marks the loan is a starting question, not a verdict. In plain English: a wider spread (e.g. S+575 vs S+525) or a lower mark (e.g. 96 vs 100 cents on the dollar) can mean that lender is pricing in more risk — but marks can also differ for reasons other than a credit view: a different tranche (second lien should price wider than first lien on the same company), a different vintage or entry point, an older filing date, or each manager’s own fair-value methodology. Compare like-for-like — check the Type and Filing columns before reading a gap as disagreement. Each row is one debt position at one BDC’s most recent filing. Source: SEC EDGAR Schedule of Investments (public).
Want to read these numbers like an analyst? Free Oxford Ledge lessons: reading a BDC’s Schedule of Investments, key credit metrics, and the Five Cs of credit analysis.